# S3 Table. Reactogenicity to rVSV-ZEBOV-GP vaccine until day 28 in vaccinees without baseline ZEBOV-specific antibodies∙

|  |  |  |  |
| --- | --- | --- | --- |
|  | Adults | Children | Adolescent |
| Adverse | **All adults** | **3x103 PFU, n=13** | **3x104 PFU, n=11** | **3x105 PFU, n=19** | **3x106 PFU, n=28** | **2x107 PFU, n=7** | **2x107 PFU, n=18** | **2x107 PFU, n=20** |
| Events | **N** | **E (%)** | **N** | **E (%)** | **N** | **E (%)** | **N** | **E (%)** | **N** | **E (%)** | **N** | **E (%)** | **N** | **E (%)** | **N** | **E (%)** |
| ***Any event*** |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Mild | 76 | 234 (68) | 12 | 33 (63∙5) | 10 | 26 (66∙7) | 19 | 54 (65∙1) | 28  | 97 (70∙3) | 7 | 24 (75) | 18 | 87 (82∙1) | 20 | 79 (80∙6) |
| Moderate | 40 | 110 (32) | 7 | 19 (36∙5) | 6 | 13 (33∙3) | 11 | 29 (34∙9) | 13 | 41 (29∙7) | 3 | 8 (25) | 7 | 19 (17∙9) | 6 | 19 (19∙4) |
| ***Solicited injection site reactions*** |  |  |  |  |
| **Pain**  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Mild | 29 | 32 (91∙4) | 3 | 4 (100) | 3 | 3 (75) | 3 | 3 (100) | 16 | 16 (100) | 4 | 6 (75) | 9 | 9 (75) | 8 | 8 (80) |
| Moderate | 3 | 3 (8∙6) | 0 | 0 (0) | 1 | 1 (25) | 0 | 0 (0) | 0 | 0 (0) | 2 | 2 (25) | 2 | 3 (25) | 2 | 2 (20) |
| **Swelling**  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Mild | 0 | 0 (0) | 0 | 0 (0) | 0 | 0 (0) | 0 | 0 (0) | 0 | 0 (0) | 0 | 0 (0) | 0 | 0 (0) | 1 | 100 (0) |
| Moderate | 0 | 0 (0) | 0 | 0 (0) | 0 | 0 (0) | 0 | 0 (0) | 0 | 0 (0) | 0 | 0 (0) | 0 | 0 (0) | 0 | 0 (0) |
| ***Solicited systemic reactions*** |  |  |  |  |
| **Fatigue**  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Mild | 24 | 26 (72∙2) | 3 | 3 (75) | 3 | 3 (100) | 7 | 7 (70) | 9 | 11 (68∙8) | 2 | 2 (66∙7) | 9 | 10 (83∙3) | 3 | 3 (42∙9) |
| Moderate | 10 | 10 (27∙8) | 1 | 1 (25) | 0 | 0 (0) | 3 | 3 (30) | 5 | 5 (31∙2) | 1 | 1 (33∙3) | 2 | 2 (16∙7) | 4 | 4 (57∙1) |
| **Headache**  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Mild | 26 | 32 (68∙1) | 5 | 6 (60) | 3 | 5 (100) | 6 | 7 (63∙6) | 9 | 10 (62∙5) | 3 | 4 (80) | 8 | 9 (90) | 11 | 13 (81∙2) |
| Moderate | 13 | 15 (31∙9) | 3 | 4 (40) | 0 | 0 (0) | 3 | 4 (36∙4) | 6 | 6 (37∙5) | 1 | 1 (20) | 1 | 1 (10) | 3 | 3 (18∙8) |
| **Myalgia** |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Mild | 9 | 9 (64∙3) | 2 | 2 (66∙7) | 0 | 0 (0) | 1 | 1 (50) | 6 | 6 (66∙7) | 0 | 0 (0) | 3 | 3 (75) | 5 | 5 (83∙3) |
| Moderate | 5 | 5 (35∙7) | 1 | 1 (33∙3) | 0 | 0 (0) | 1 | 1 (50) | 3 | 3 (33∙3) | 0 | 0 (0) | 1 | 1 (25) | 1 | 1 (16∙7) |
| **Subjective fever**  |  |  |  |  |
| Mild | 16 | 18 (78∙3) | 1 | 1 (50) | 2 | 2 (50) | 1 | 2 (100) | 9 | 10 (83∙3) | 3 | 3 (100) | 7 | 9 (90) | 7 | 9 (90) |
| Moderate | 5 | 5 (21∙7) | 1 | 1 (50) | 2 | 2 (50) | 0 | 0 (0) | 2 | 2 (16∙7) | 0 | 0 (0) | 1 | 1 (10) | 1 | 1 (10) |
| **Objective fever**  |  |  |  |  |  |
| Mild | 10 | 11 (84∙6) | 3 | 4 (100) | 1 | 1 (100) | 1 | 1 (100) | 3 | 3 (60) | 2 | 2 (100) | 7 | 7 (100) | 5 | 5 (100) |
| Moderate | 1 | 2 (15∙4) | 0 | 0 (0) | 0 | 0 (0) | 0 | 0 (0) | 2 | 2 (40) | 0 | 0 (0) | 0 | 0 (0) | 0 | 0 (0) |
| **Chills** |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Mild | 3 | 3 (100) | 0 | 0 (0) | 0 | 0 (0) | 0 | 0 (0) | 3 | 3 (100) | 0 | 0 (0) | 5 | 5 (100) | 3 | 3 (100) |
| Moderate | 0 | 0 (0) | 0 | 0 (0) | 0 | 0 (0) | 0 | 0 (0) | 0 | 0 (0) | 0 | 0 (0) | 0 | 0 (0) | 0 | 0 (0) |
| **Arthralgia** |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Mild | 7 | 8 (38∙1) | 1 | 1 (20) | 0 | 0 (0) | 0 | 0 (0) | 5 | 6 (60) | 1 | 1 (33∙3) | 3 | 3 (75) | 3 | 3 (75) |
| Moderate | 12 | 13 (61∙9) | 3 | 4 (80) | 1 | 1 (100) | 2 | 2 (100) | 4 | 4 (40) | 2 | 2 (66∙7) | 1 | 1 (25) | 1 | 1 (25) |
| **Mouth ulcer** |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Mild | 4 | 4 (80) | 0 | 0 (0) | 0 | 0 (0) | 1 | 1 (100) | 2 | 2 (100) | 1 | 1 (50) | 1 | 1 (50) | 0 | 0 (0) |
| Moderate | 1 | 1 (20) | 0 | 0 (0) | 0 | 0 (0) | 0 | 0 (0) | 0 | 0 (0) | 1 | 1 (50) | 1 | 1 (50) | 0 | 0 (0) |
| **Skin lesion** |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Mild | 4 | 4 (80) | 0 | 0 (0) | 0 | 0 (0) | 0 | 0 (0) | 0 | 0 (0) | 4 | 4 (80) | 1 | 1 (100) | 2 | 2 (100) |
| Moderate | 1 | 1 (20) | 0 | 0 (0) | 0 | 0 (0) | 0 | 0 (0) | 0 | 0 (0) | 1 | 1 (20) | 0 | 0 (0) | 0 | 0 (0) |
| Blister |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Mild | 1 | 1 (100) | 0 | 0 (0) | 0 | 0 (0) | 0 | 0 (0) | 0 | 0 (0) | 1 | 1 (100) | 0 | 0 (0) | 0 | 0 (0) |
| Moderate | 0 | 0 (0) | 0 | 0 (0) | 0 | 0 (0) | 0 | 0 (0) | 0 | 0 (0) | 0 | 0 (0) | 0 | 0 (0) | 0 | 0 (0) |
| **Gastrointestinal symptoms** |  |  |  |  |
| Mild | 24 | 27 (77∙1) | 3 | 3 (100) | 3 | 3 (50) | 7 | 8 (72∙7) | 8 | 10 (83∙3) | 3 | 3 (100) | 9 | 12 (80) | 6 | 10 (76∙9) |
| Moderate | 5 | 8 (22∙9) | 0 | 0 (0) | 1 | 3 (50) | 3 | 3 (27∙3) | 1 | 2 (16∙7) | 0 | 0 (0) | 2 | 3 (20) | 3 | 3 (23∙1) |
| ***Unsolicited adverse events*** |  |  |  |  |
| **Malaria** |  |  |  |  |  |
| Mild | 4 | 4 (23∙5) | 1 | 1 (100) | 0 | 0 (0) | 0 | 0 (0) | 0 | 0 (0) | 3 | 3 (42∙9) | 0 | 0 (0) | 2 | 2 (66∙7)  |
| Moderate | 11 | 13 (76∙5) | 0 | 0 (0) | 0 | 0 (0) | 5 | 6 (100) | 2 | 3 (100) | 4 | 4 (57∙1) | 2 | 2 (100) | 1 | 1 (33∙3) |
| **Rhinitis** |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Mild | 9 | 9 (100) | 2 | 2 (100) | 1 | 1 (100) | 2 | 2 (100) | 0 | 0 (0) | 4 | 4 (100) | 1 | 1 (100) | 3 | 3 (100)  |
| Moderate | 0 | 0 (0) | 0 | 0 (0) | 0 | 0 (0) | 0 | 0 (0) | 0 | 0 (0) | 0 | 0 (0) | 0 | 0 (0) | 0 | 0 (0) |
| **Cough** |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Mild | 7 | 8 (66∙7) | 2 | 2 (40) | 2 | 2 (66∙7) | 0 | 0 (0) | 0 | 0 (0) | 3 | 4 (100) | 1 | 1 (100) | 0 | 0 (0) |
| Moderate | 4 | 4 (33∙3) | 3 | 3 (60) | 1 | 1 (33∙3) | 0 | 0 (0) | 0 | 0 (0) | 0 | 0 (0) | 0 | 0 (0) | 0 | 0 (0) |
| **Other** |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Mild | 51 | 74 (67∙3) | 3 | 5 (45∙5) | 4 | 7 (58∙3) | 15 | 22 (68∙8) | 13 | 18 (64∙3) | 16 | 22 (81∙5) | 8 | 11 (84∙6) | 6 | 8 (100) |
| Moderate | 24 | 36 (32∙7) | 3 | 6 (54∙5) | 4 | 5 (41∙7) | 7 | 10 (31∙2) | 5 | 10 (35∙7) | 5 | 5 (18∙5) | 2 | 2 (15∙4) | 0 | 0 (0) |
| N: Number of participants reporting at least one event∙ All events are reported for each doseE: Number of all events reported%: Percentage of all events reported |